Skip Navigation


Physician Scientist Pathway

physician scientists talking in a group

The Physician Scientist Pathway (PSP) is a post-graduate training program intended to produce clinically well-trained scientists with interests ranging from basic to translational and clinical research.

Our goal is to recruit, inspire, develop and retain physician scientists who will make scientific breakthroughs for the future of medicine. This pathway formalizes a long tradition of these goals at Johns Hopkins.

About the Program

The DOM provides a pathway for physicians within the Osler Medical Residency and the Bayview Internal Medicine Residency to develop robust biomedical research careers geared toward improving human health and has created a vigorous research and educational environment with strong mentorship and support.

The Physician Scientist Pathway program aims to:

  1. Expose trainees to broad intensive clinical training. Some of the most important research questions come from the bedside.
  2. Foster an environment of intellectual curiosity through exposure to PhD, MD/PhD and MD scientists throughout the University. This will occur through clinical rotations, journal clubs, specialized lectures and social events with Johns Hopkins scientists.
  3. Develop research goals and fellowship plans and facilitate meetings with Johns Hopkins researchers in the trainees’ area of interest.

Several reports published during the past 35 years have chronicled the decrease in physician-scientists in the biomedical workforce. Learn more about the JHSOM Physician Scientist Training Program.

Pathway Structure

The pathway consists of two or three years of intensive clinical work and is designed to meet all criteria required by the American Board of Internal Medicine (ABIM) for certification eligibility. Participants have the opportunity to enter the ABIM Research Training Research Pathway after two years in the standard program (i.e. subspecialty short track). This decision is made in consultation with the Program Director in the middle of the intern year and allows qualified candidates to begin their sub-specialty fellowship training in lieu of their third year of residency. This is not required and categorical (three years) candidates can also participate in the PSP. For more details of the ABIM Research Training Pathway see the American Board of Medical Specialties (ABMS) report on physician scientists.



Robert Brodsky

Robert A. Brodsky, M.D., is a professor of Medicine and Oncology. He is on the editorial board for Blood, an associate editor for the Journal of Clinical Investigation and on the executive committee of the American Society of Hematology. Dr. Brodsky’s clinical and academic interests relate to bone marrow failure disorders, hemolytic anemias and complement. He and his colleagues pioneered the use of high-dose cyclophosphamide for treating autoimmunity and alloimmunity. He has a special interest in using post-transplant cyclophosphamide to prevent graft versus host disease and to expand the donor pool to include HLA-haploidentical donors for aplastic anemia and severe hemoglobinopathies.


Associate Directors

Rachel Damico

Rachel L. Damico, M.D., Ph.D., is an associate professor in the Division of Pulmonary and Critical Care Medicine. Her research has focused on the molecular determinants of vascular injury and their relationship to the pathogenesis of multiple pulmonary disease states, including acute respiratory distress syndrome, pulmonary arterial hypertension and emphysema. As an active investigator in the Johns Hopkins Pulmonary Hypertension Program, she has participated in both clinical and translational research in pulmonary arterial hypertension, and she leads basic and translational projects on the molecular determinants of disease severity in pulmonary arterial hypertension.



Dr. Venkataramana

Ramana K. Sidhaye, M.D., is an associate professor in the Division of Pulmonary and Critical Care Medicine. Her research has focused on basic mechanisms of lung epithelial tissue integrity disruption in the setting of chronic environmental exposures and patient-based susceptibility to these insults. She is also investigating mechanisms by which rectification of the epithelial barrier improves lung function in the context of multiple pulmonary disease states, including COPD and asthma.




See All Pathway Leaders

back to top button